Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant.

Braz J Med Biol Res. 2000 Jul;33(7):779-89. Unique Identifier : AIDSLINE MED/20340943
Muccioli C; Belfort R Jr; Departamento de Oftalmologia, Escola Paulista de Medicina,; Universidade Federal de Sao Paulo, Sao Paulo, SP, Brasil.; eyebr@webmail.epm.br


Abstract: The objective of this prospective study was to evaluate the efficacy and complications of the use of an intraocular sustained-release ganciclovir implant for the treatment of active cytomegalovirus (CMV) retinitis in AIDS patients. Thirty-nine eyes of 26 patients were submitted to ocular surgery. All patients underwent complete ocular examination before and after surgery. The surgical procedure was always done under local anesthesia using the same technique. The mean time for the surgical procedure was 20 min (range, 15 to 30 min). The average follow-up period was 3.7 months. Of all patient, only 4 presented recurrence of retinitis after 8, 8, 9 and 2 months, respectively. Three of them received a successful second implant. All 39 eyes of the 26 patients presented healing of retinitis as shown by clinical improvement evaluated by indirect binocular ophthalmoscopy and retinography. Retinitis healed within a period of 4 to 6 weeks in all patients, with clinical regression signs from the third week on. Six (15.4%) eyes developed retinal detachment. None of the patients developed CMV retinitis in the contralateral eye. The intraocular implant proved to be effective in controlling the progression of retinitis for a period of up to 8 months even in patients for whom systemic therapy with either ganciclovir or foscarnet or both had failed. The intraocular sustained-release ganciclovir implant proved to be a safe new procedure for the treatment of CMV retinitis, avoiding the systemic side effects caused by the intravenous medications and improving the quality of life of the patients.


Keywords: CLINICAL TRIAL JOURNAL ARTICLE Adult Antiviral Agents/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS AIDS-Related Opportunistic Infections/COMPLICATIONS/*DRUG THERAPY Cytomegalovirus Retinitis/*DRUG THERAPY/SURGERY Delayed-Action Preparations Drug Implants Female Follow-Up Studies Ganciclovir/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Human Male Middle Age Prospective Studies Support, Non-U.S. Gov't Treatment Outcome Visual Acuity

KWDclinicaltrialjournalarticleadultantiviralagents/KWDadministration&dosage/adverseeffectsaids-relatedopportunisticinfections/complications/KWDdrugtherapycytomegalovirusretinitis/KWDdrugtherapy/surgerydelayed-actionpreparationsdrugimplantsfemalefollow-upstudiesganciclovir/KWDadministration&dosage/adverseeffectshumanmalemiddleageprospectivestudiessupport,non-uKWDsKWDgov'ttreatmentoutcomevisualacuity
001130
A00B1198


Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .